Novel Therapy Approved by the European Commission for Hidradenitis suppurativa/Acne inversa
Only recently (July 2015), the European Commission and the FDA (US Food and Drug Administration) has approved a novel drug for Hidradenitis suppurativa/Acne inversa (HS). It is the first and only approved drug for HS. HS is a chronic inflammatory disease which is characterized by recurrent, painful abscesses leading also to psychological impairment. Until now,
